Lova L. Sun, MD, MSCE

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Headshot of Lova L. Sun, MD, MSCE
Penn Medicine Provider

About me

  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Massachusetts General Hospital
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Reviews

Average Rating

250 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
just everything
Anonymous
April 2026
she's very open to questions and exhibit patience.
Anonymous
April 2026
very kind and explained things well
Anonymous
March 2026
she spends time with you and shows sincerity and caring.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Sun is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

VLova Sun, Barbara Burtness, Yael Flamand, Laila A. Gharzai, Mei Tang, Nabil F. Saba EA3231: A randomized phase III study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with BRAF V600Em. , J Clin Oncol: 2026


Lova Sun, Max M. Wattenberg, Devora Delman, Kelly Markowitz, Jalal Jalaly, Devraj Basu, Robert Brody, Gregory S. Weinstein, Steven Cannady, James Gates, Karthik Rajasekaran, D Gregory Farwell, Ryan Carey, Ara Chalian, Christopher Rassekh, Aditi P. Singh, E. Paul Wileyto, Roger B. Cohen, Gregory L. Beatty A prospective trial of single-dose neoadjuvant PD-1 blockade with or without a CD40 agonist in HPV-negative HNSCC. , J Clin Oncol: 2026


Xavier Orcutt, Vivek Nimgaonkar, Lova Sun, Charu Aggarwal, Aaron B. Cohen, Ronac Mamtani, Qi Long, Ravi B. Parikh Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab. , J Clin Oncol: 2026


Adam Barsouk, Jonathan H. Sussman, Maxim Yaskolko, Lova Sun, Aditi P. Singh, Charu Aggarwal, Roger B. Cohen, Melina E. Marmarelis, Corey J. Langer Performance status and tarlatamab outcomes in a large, multi-institution real-world database of 2L+ ES-SCLC. , J Clin Oncol: 2026


Rachel Jaber Chehayeb, Willdragon Wang, Lova Sun, Aditi P. Singh, Roger B. Cohen, Corey J. Langer, Charu Aggarwal, Melina E. Marmarelis Incidentally discovered lung cancer in explanted lungs at the time of lung transplantation: Management and outcomes. , J Clin Oncol: 2026


Xavier Orcutt, Vivek Nimgaonkar, Lova Sun, Charu Aggarwal, Aaron B. Cohen, Ronac Mamtani, Qi Long, Ravi B. Parikh Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumab. , J Clin Oncol: 2026


Phurin Areesawangkit, Adam Barsouk, Maxim Yaskolko, Lucy Wang, Cole Friedes, Roger B. Cohen, Lova Sun, Charu Aggarwal, Melina E. Marmarelis, Aditi P. Singh, Kyle W. Robinson, Christopher D'Avella, Christine A. Ciunci, Steven J. Feigenberg, Jeffrey D. Bradley, Nikhil Yegya-Raman, Michelle Iocolano, Christiana Davis, Corey J. Langer Long-term survival outcomes of consolidative local ablative therapy after response to first-line systemic treatment in oligometastatic NSCLC. , J Clin Oncol: 2026


Millet YA, Spira AI, Baik CS, Hong MH, Shum E, Patel JD, Nguyen D, Janne PA, Piotrowska Z, Leighl NB, Matsumoto S, Sun L, Yang TY, Yoshida T, Nilsson MB, Heymach JV, Murray BW, Keats J, Lee S, Hsieh J, Zalutskaya A, Le X. BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations , Mol Cancer Ther: 2026


Adam Barsouk, Maxim Yaskolko, Jonathan H. Sussman, Lova Sun, Roger B. Cohen, Charu Aggarwal, Corey J. Langer, Melina E. Marmarelis Sotorasib vs adagrasib in the 2L+ setting: Outcomes in a large, multi-institutional, real-world database of KRAS-G12C mutated mNSCLC , J Clin Oncol: 2026


Vikram Vasan, Lovely Raghav, Malay K. Sannigrahi, Robert Brody, Alexander Lin, John N. Lukens, Lova Sun, Iain M. Morgan, Ahmed Diab, Jalal Jalaly, Devraj Basu Biologic and clinical implications of HPV genome state variation in oropharyngeal cancers , J Clin Oncol: 2026